Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael A. Schwarzschild, M.D., PH.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Overview

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. U01NS107009 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2018 - Apr 30, 2023
    NIH/NINDS
    Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts
    Role: Principal Investigator
  2. U13NS103523 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2017 - Jun 30, 2018
    NIH/NINDS
    2017 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  3. R13NS098746 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2016 - Jul 31, 2017
    NIH/NINDS
    2016 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  4. (Michael Schwarzschild) Jan 1, 2016 - Dec 31, 2019
    Michael J. Fox Foundation
    Blood Sampling for Future Biomarker Research
  5. U01NS090259 (SCHWARZSCHILD, MICHAEL A) Sep 1, 2015 - Jun 30, 2020
    NIH/NINDS
    Phase 3 trial of inosine for Parkinson's disease CCC
    Role: Principal Investigator

Featured Content

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, Ascherio A. Prediagnostic plasma branched chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. 2018 Nov 14. PMID: 30429276.
    View in: PubMed
  2. Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. EBioMedicine. 2018 Nov; 37:259-268. PMID: 30415890.
    View in: PubMed
  3. Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533. PMID: 30564619.
    View in: PubMed
  4. Bhattacharyya S, Macklin EA, Schwarzschild MA. Cardiovascular Safety of Febuxostat. N Engl J Med. 2018 10 18; 379(16):1582. PMID: 30338966.
    View in: PubMed
  5. Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Mov Disord. 2018 Sep; 33(9):1492-1496. PMID: 30218460.
    View in: PubMed
  6. Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. J Neurol Sci. 2018 Nov 15; 394:41-44. PMID: 30212740.
    View in: PubMed
  7. Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018 Dec; 89(12):1288-1295. PMID: 30076266.
    View in: PubMed
  8. Bakshi R, Xu Y, Mueller KA, Chen X, Granucci E, Paganoni S, Sadri-Vakili G, Schwarzschild MA. Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice. Mol Cell Neurosci. 2018 Oct; 92:12-16. PMID: 29928993.
    View in: PubMed
  9. Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism Relat Disord. 2018 Aug; 53:4-9. PMID: 29789205.
    View in: PubMed
  10. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. 2018 May 08; 90(19):e1646-e1653. PMID: 29643081.
    View in: PubMed
  11. Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine. 2018 Mar; 29:13-22. PMID: 29433982.
    View in: PubMed
  12. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018 Mar; 33(3):414-420. PMID: 29318639.
    View in: PubMed
  13. O'Reilly ÉJ, Bjornevik K, Schwarzschild MA, McCullough ML, Kolonel LN, Le Marchand L, Manson JE, Ascherio A. Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):194-200. PMID: 29277115.
    View in: PubMed
  14. Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Mov Disord. 2017 Nov; 32(11):1501-1503. PMID: 28976040.
    View in: PubMed
  15. Palacios N, Fitzgerald KC, Hart JE, Weisskopf M, Schwarzschild MA, Ascherio A, Laden F. Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men. Environ Health Perspect. 2017 08 18; 125(8):087011. PMID: 28886605.
    View in: PubMed
  16. Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017 12; 298(Pt B):210-224. PMID: 28622913.
    View in: PubMed
  17. Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. 2017 Jul 04; 89(1):46-52. PMID: 28596209.
    View in: PubMed
  18. Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proc Natl Acad Sci U S A. 2017 06 06; 114(23):E4676-E4685. PMID: 28533375.
    View in: PubMed
  19. Chen X, Feng D, Schwarzschild MA, Gao X. Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis. Ann Clin Transl Neurol. 2017 03; 4(3):212-216. PMID: 28275654.
    View in: PubMed
  20. Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017 03; 32(3):319-324. PMID: 28233927.
    View in: PubMed
  21. Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. Ann Neurol. 2017 Mar; 81(3):395-406. PMID: 28019657.
    View in: PubMed
  22. Schwarzschild MA. Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? J Parkinsons Dis. 2017; 7(1):79-80. PMID: 28035939.
    View in: PubMed
  23. Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics. 2017 01; 14(1):148-153. PMID: 27995438.
    View in: PubMed
  24. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. J Parkinsons Dis. 2017; 7(4):677-684. PMID: 28984617.
    View in: PubMed
  25. Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of antioxidant vitamins and risk of Parkinson's disease. Mov Disord. 2016 12; 31(12):1909-1914. PMID: 27787934.
    View in: PubMed
  26. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016 Nov; 15(12):1257-1272. PMID: 27751556.
    View in: PubMed
  27. O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017 02; 18(1-2):120-125. PMID: 27677562.
    View in: PubMed
  28. Jackson EK, Boison D, Schwarzschild MA, Kochanek PM. Purines: forgotten mediators in traumatic brain injury. J Neurochem. 2016 Apr; 137(2):142-53. PMID: 26809224; PMCID: PMC4828259 [Available on 04/01/17].
    View in: PubMed, PubMed Central
  29. Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience. 2016 May 13; 322:129-37. PMID: 26905951; PMCID: PMC4805447 [Available on 05/13/17].
    View in: PubMed, PubMed Central
  30. Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Mov Disord. 2016 Mar; 31(3):417-21. PMID: 26805433.
    View in: PubMed
  31. Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. 2016 Feb 09; 86(6):520-6. PMID: 26764029; PMCID: PMC4753729 [Available on 02/09/17].
    View in: PubMed, PubMed Central
  32. Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis. 2015 Oct; 82:574-579. PMID: 26341543; PMCID: PMC4641017 [Available on 10/01/16].
    View in: PubMed, PubMed Central
  33. Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR. Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71. PMID: 26220939; PMCID: PMC4643625.
    View in: PubMed, PubMed Central
  34. Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One. 2015; 10(1):e0116919. PMID: 25608039; PMCID: PMC4301865.
    View in: PubMed, PubMed Central
  35. Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environ Health. 2014 Oct 07; 13:80. PMID: 25294559; PMCID: PMC4201741.
    View in: PubMed, PubMed Central
  36. Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol. 2014 Dec; 76(6):862-8. PMID: 25257975; PMCID: PMC4245314.
    View in: PubMed, PubMed Central
  37. Schwarzschild MA, Macklin EA, Ascherio A. Urate and neuroprotection trials. Lancet Neurol. 2014 Aug; 13(8):758. PMID: 25030508.
    View in: PubMed
  38. Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environ Health Perspect. 2014 Sep; 122(9):933-8. PMID: 24905870; PMCID: PMC4154211.
    View in: PubMed, PubMed Central
  39. Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 2014 Aug 22; 274:242-9. PMID: 24880154; PMCID: PMC4120965.
    View in: PubMed, PubMed Central
  40. Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Res. 2014 May 14; 1563:103-9. PMID: 24680743; PMCID: PMC4146456.
    View in: PubMed, PubMed Central
  41. Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 2014 Feb 01; 37(2):369-72. PMID: 24497665; PMCID: PMC3900617.
    View in: PubMed, PubMed Central
  42. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103; PMCID: PMC3940333.
    View in: PubMed, PubMed Central
  43. McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not a-synuclein-induced neuronal cell loss. PLoS One. 2014; 9(1):e86048. PMID: 24465863; PMCID: PMC3896461.
    View in: PubMed, PubMed Central
  44. Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics. 2014 Jan; 11(1):34-46. PMID: 24310604; PMCID: PMC3899482.
    View in: PubMed, PubMed Central
  45. Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7. PMID: 24068787; PMCID: PMC3888173.
    View in: PubMed, PubMed Central
  46. McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neurodegener Dis. 2013; 12(4):189-98. PMID: 23467193; PMCID: PMC3809155.
    View in: PubMed, PubMed Central
  47. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054; PMCID: PMC3608707.
    View in: PubMed, PubMed Central
  48. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis. 2013 Jan 01; 3(3):231-9. PMID: 24018336; PMCID: PMC4318242.
    View in: PubMed, PubMed Central
  49. Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):300-5. PMID: 23248282; PMCID: PMC3538212.
    View in: PubMed, PubMed Central
  50. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Arch Neurol. 2012 Oct 1; 69(10):1381. PMID: 23044597.
    View in: PubMed
  51. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Arch Neurol. 2012 Oct 01; 69(10):1381. PMID: 23754004.
    View in: PubMed
  52. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord. 2012 Sep 15; 27(11):1392-7. PMID: 22976926.
    View in: PubMed
  53. Salamone JD, Collins-Praino LE, Pardo M, Podurgiel SJ, Baqi Y, Müller CE, Schwarzschild MA, Correa M. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor. Eur Neuropsychopharmacol. 2013 Aug; 23(8):972-7. PMID: 22947264.
    View in: PubMed
  54. Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord. 2012 Sep 01; 27(10):1276-82. PMID: 22927157; PMCID: PMC3554265.
    View in: PubMed, PubMed Central
  55. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem. 2012 Oct; 123(1):172-81. PMID: 22671773; PMCID: PMC3438313.
    View in: PubMed, PubMed Central
  56. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep. 2012 Aug; 12(4):367-75. PMID: 22580741.
    View in: PubMed
  57. Schwarzschild MA. Caffeine in Parkinson disease: better for cruise control than snooze patrol? Neurology. 2012 Aug 14; 79(7):616-8. PMID: 22855870.
    View in: PubMed
  58. Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov Disord. 2012 Jul; 27(8):980-7. PMID: 22714720; PMCID: PMC3548327.
    View in: PubMed, PubMed Central
  59. Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed Chromatogr. 2013 Jan; 27(1):122-9. PMID: 22674671.
    View in: PubMed
  60. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One. 2012; 7(5):e37331. PMID: 22606360; PMCID: PMC3351394.
    View in: PubMed, PubMed Central
  61. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 2012 Apr 10; 78(15):1138-45. PMID: 22491871; PMCID: PMC3320056.
    View in: PubMed, PubMed Central
  62. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012 Mar; 69(3):380-4. PMID: 22410446; PMCID: PMC3398841.
    View in: PubMed, PubMed Central
  63. Matos M, Augusto E, Santos-Rodrigues AD, Schwarzschild MA, Chen JF, Cunha RA, Agostinho P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia. 2012 May; 60(5):702-16. PMID: 22298379.
    View in: PubMed
  64. Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an a-synuclein model of Parkinson's disease. Ann Neurol. 2012 Feb; 71(2):278-82. PMID: 22367999; PMCID: PMC3292742.
    View in: PubMed, PubMed Central
  65. Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. J Parkinsons Dis. 2012; 2(2):153-60. PMID: 23939439; PMCID: PMC3744127.
    View in: PubMed, PubMed Central
  66. Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, Unni VK, Hung AY, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Sudarsky LR, Growdon JH, Ivinson AJ, Hyman BT, Scherzer CR. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord. 2011 Oct; 26(12):2283-6. PMID: 21953863; PMCID: PMC3337217.
    View in: PubMed, PubMed Central
  67. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One. 2011; 6(8):e22854. PMID: 21853051; PMCID: PMC3154909.
    View in: PubMed, PubMed Central
  68. Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord. 2011 Oct; 26(12):2253-9. PMID: 21739472; PMCID: PMC3627531.
    View in: PubMed, PubMed Central
  69. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am J Epidemiol. 2011 Sep 01; 174(5):546-51. PMID: 21719744; PMCID: PMC3202149.
    View in: PubMed, PubMed Central
  70. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord. 2011 Aug 15; 26(10):1864-8. PMID: 21538532; PMCID: PMC3150627.
    View in: PubMed, PubMed Central
  71. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011 Mar 08; 76(10):863-9. PMID: 21368281; PMCID: PMC3059148.
    View in: PubMed, PubMed Central
  72. Barkhoudarian MT, Schwarzschild MA. Preclinical jockeying on the translational track of adenosine A2A receptors. Exp Neurol. 2011 Apr; 228(2):160-4. PMID: 21211537; PMCID: PMC3073659.
    View in: PubMed, PubMed Central
  73. Schwarzschild MA. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010 Nov 23; 75(21):1943-4; author reply 1944-5. PMID: 21098412.
    View in: PubMed
  74. Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and Parkinson's disease in men. Mov Disord. 2010 Nov 15; 25(15):2654-7. PMID: 20737545; PMCID: PMC3114885.
    View in: PubMed, PubMed Central
  75. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med. 2010 Oct; 4(5):701-12. PMID: 20945982; PMCID: PMC3049925.
    View in: PubMed, PubMed Central
  76. Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett. 2010 Dec 17; 486(3):161-5. PMID: 20854878; PMCID: PMC2970925.
    View in: PubMed, PubMed Central
  77. Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1818-22. PMID: 20669249; PMCID: PMC2939261.
    View in: PubMed, PubMed Central
  78. Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A1 or A(2A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res. 2011 Jan 07; 1367:310-8. PMID: 20828543; PMCID: PMC3005012.
    View in: PubMed, PubMed Central
  79. Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson's disease. Mov Disord. 2010 Aug 15; 25(11):1560-7. PMID: 20740569; PMCID: PMC3132935.
    View in: PubMed, PubMed Central
  80. O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Plasma urate and Parkinson's disease in women. Am J Epidemiol. 2010 Sep 15; 172(6):666-70. PMID: 20682521; PMCID: PMC2950819.
    View in: PubMed, PubMed Central
  81. Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism Relat Disord. 2010 Jul; 16(6):370-5. PMID: 20304699; PMCID: PMC2916058.
    View in: PubMed, PubMed Central
  82. Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol. 2010 Jun; 223(2):657-61. PMID: 20188092; PMCID: PMC2864327.
    View in: PubMed, PubMed Central
  83. Schwarzschild MA. Rasagiline in Parkinson's disease. N Engl J Med. 2010 Feb 18; 362(7):658; author reply 658-9. PMID: 20187261.
    View in: PubMed
  84. Youdim MB. Rasagiline in Parkinson's disease. N Engl J Med. 2010 Feb 18; 362(7):657-8; author reply 658-9. PMID: 20164492.
    View in: PubMed
  85. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 2010 May 05; 167(2):475-81. PMID: 20167258; PMCID: PMC2849921.
    View in: PubMed, PubMed Central
  86. Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and erectile dysfunction. Sleep. 2010 Jan; 33(1):75-9. PMID: 20120623; PMCID: PMC2802250.
    View in: PubMed, PubMed Central
  87. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010; 183:183-208. PMID: 20696321; PMCID: PMC3102301.
    View in: PubMed, PubMed Central
  88. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8. PMID: 19822770; PMCID: PMC2795011.
    View in: PubMed, PubMed Central
  89. Quiroz C, Luján R, Uchigashima M, Simoes AP, Lerner TN, Borycz J, Kachroo A, Canas PM, Orru M, Schwarzschild MA, Rosin DL, Kreitzer AC, Cunha RA, Watanabe M, Ferré S. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal. 2009 Nov 18; 9:1321-44. PMID: 19936569; PMCID: PMC2871285.
    View in: PubMed, PubMed Central
  90. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009 Oct 20; 73(16):1286-91. PMID: 19841380; PMCID: PMC2764417.
    View in: PubMed, PubMed Central
  91. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem. 2009 Dec; 111(6):1478-89. PMID: 19817968; PMCID: PMC2820161.
    View in: PubMed, PubMed Central
  92. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1359-65. PMID: 19424986; PMCID: PMC2751573.
    View in: PubMed, PubMed Central
  93. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009 May; 68(5):515-24. PMID: 19525899; PMCID: PMC2753269.
    View in: PubMed, PubMed Central
  94. Gao X, Schwarzschild MA, Wang H, Ascherio A. Obesity and restless legs syndrome in men and women. Neurology. 2009 Apr 07; 72(14):1255-61. PMID: 19349606; PMCID: PMC2677487.
    View in: PubMed, PubMed Central
  95. O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. Am J Epidemiol. 2009 Mar 15; 169(6):678-82. PMID: 19131566; PMCID: PMC2727210.
    View in: PubMed, PubMed Central
  96. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol. 2009 Jan; 65(1):76-82. PMID: 19194882; PMCID: PMC2639631.
    View in: PubMed, PubMed Central
  97. Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics. 2009 Jan; 6(1):141-51. PMID: 19110205.
    View in: PubMed
  98. Yang JN, Björklund O, Lindström-Törnqvist K, Lindgren E, Eriksson TM, Kahlström J, Chen JF, Schwarzschild MA, Tobler I, Fredholm BB. Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol (1985). 2009 Feb; 106(2):631-9. PMID: 19036889; PMCID: PMC2644247.
    View in: PubMed, PubMed Central
  99. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. PMID: 19066433; PMCID: PMC2745303.
    View in: PubMed, PubMed Central
  100. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, Logroscino G, Nelson L, Ravina B, Rocca W, Ross GW, Schettler T, Schwarzschild M, Scott B, Seegal R, Singleton A, Steenland K, Tanner CM, Van Den Eeden S, Weisskopf M. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21. PMID: 19165397; PMCID: PMC2627854.
    View in: PubMed, PubMed Central
  101. Tikh EI, Fenton RA, Chen JF, Schwarzschild MA, Dobson JG. Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart. J Cell Physiol. 2008 Jul; 216(1):83-90. PMID: 18181173.
    View in: PubMed
  102. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23. PMID: 18413464; PMCID: PMC2574855.
    View in: PubMed, PubMed Central
  103. Gao X, Chen H, Schwarzschild MA, Logroscino G, Ascherio A. Perceived imbalance and risk of Parkinson's disease. Mov Disord. 2008 Mar 15; 23(4):613-6. PMID: 18181208.
    View in: PubMed
  104. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008 Apr 01; 167(7):831-8. PMID: 18326873.
    View in: PubMed
  105. Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA, Ascherio A. Telomere length and risk of Parkinson's disease. Mov Disord. 2008 Jan 30; 23(2):302-5. PMID: 18044760.
    View in: PubMed
  106. Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Recreational physical activity and risk of Parkinson's disease. Mov Disord. 2008 Jan; 23(1):69-74. PMID: 17960818.
    View in: PubMed
  107. Schwarzschild MA (guest editor) Zigmond M (editor). "Targeting Adenosine A2A Receptors in Parkinson's Disease and other CNS Disorders". Progress in Neurobiology [journal Special Issue]. 2007; 261-347.
  108. Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem. 2008 Jan; 104(1):279-86. PMID: 18005343.
    View in: PubMed
  109. Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr. 2007 Nov; 86(5):1486-94. PMID: 17991663.
    View in: PubMed
  110. Schwarzschild MA. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge. Prog Neurobiol. 2007 Dec; 83(5):261-2. PMID: 17997007; PMCID: PMC2147722.
    View in: PubMed, PubMed Central
  111. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008 Jan 01; 167(1):90-5. PMID: 17890755.
    View in: PubMed
  112. Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A. Erectile function and risk of Parkinson's disease. Am J Epidemiol. 2007 Dec 15; 166(12):1446-50. PMID: 17875583.
    View in: PubMed
  113. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007 Oct 23; 69(17):1688-95. PMID: 17761552.
    View in: PubMed
  114. Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr Opin Neurol. 2007 Aug; 20(4):477-83. PMID: 17620885.
    View in: PubMed
  115. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol. 2007 Dec; 83(5):293-309. PMID: 17826884.
    View in: PubMed
  116. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007 Sep 01; 166(5):561-7. PMID: 17584757.
    View in: PubMed
  117. Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007 Mar 06; 68(10):764-8. PMID: 17339584; PMCID: PMC2225169.
    View in: PubMed, PubMed Central
  118. Chen H, O'Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, Thun MJ, Ascherio A. Consumption of dairy products and risk of Parkinson's disease. Am J Epidemiol. 2007 May 01; 165(9):998-1006. PMID: 17272289.
    View in: PubMed
  119. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16; 104(3):955-60. PMID: 17215369; PMCID: PMC1766335.
    View in: PubMed, PubMed Central
  120. Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, Chen JF, Schwarzschild MA. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci. 2006 Dec 27; 26(52):13548-55. PMID: 17192438.
    View in: PubMed
  121. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006 Nov; 29(11):647-54. PMID: 17030429.
    View in: PubMed
  122. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct; 5(10):845-54. PMID: 17016425.
    View in: PubMed
  123. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. 2006 Aug; 60(2):197-203. PMID: 16802290.
    View in: PubMed
  124. Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006 Aug; 54(8):2632-42. PMID: 16871530.
    View in: PubMed
  125. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006 Jul; 21(7):1002-7. PMID: 16602107.
    View in: PubMed
  126. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, Reiss AB, Pillinger MH, Chen JF, Schwarzschild MA, Friedman SL, Cronstein BN. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol. 2006 Aug; 148(8):1144-55. PMID: 16783407; PMCID: PMC1752015.
    View in: PubMed, PubMed Central
  127. Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease. Am J Epidemiol. 2006 Apr 15; 163(8):726-30. PMID: 16495472.
    View in: PubMed
  128. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci. 2006 Jan 11; 26(2):535-41. PMID: 16407551.
    View in: PubMed
  129. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005 Dec; 58(6):963-7. PMID: 16240369.
    View in: PubMed
  130. Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci. 2005 Nov 09; 25(45):10414-9. PMID: 16280580.
    View in: PubMed
  131. Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, Grò MC, Schwarzschild MA, Chen JF, Cunha RA, Popoli P. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem. 2005 Nov; 95(4):1188-200. PMID: 16271052.
    View in: PubMed
  132. Yu L, Schwarzschild MA, Chen JF. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neurosci Lett. 2006 Jan 23; 393(1):31-5. PMID: 16236444.
    View in: PubMed
  133. Frédérick R, Ooms F, Castagnoli N, Petzer JP, Feng JF, Schwarzschild MA, Van der Schyf CJ, Wouters J. (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B. Acta Crystallogr C. 2005 Sep; 61(Pt 9):o531-2. PMID: 16143772.
    View in: PubMed
  134. Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem. 2005 Nov; 95(4):919-29. PMID: 16092928.
    View in: PubMed
  135. Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA, Weng Z, Chen JF. Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum. Physiol Genomics. 2005 Sep 21; 23(1):89-102. PMID: 16046619.
    View in: PubMed
  136. Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005 Jul; 8(7):858-9. PMID: 15965471.
    View in: PubMed
  137. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology. 2005 May; 30(5):891-900. PMID: 15602504.
    View in: PubMed
  138. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Physical activity and the risk of Parkinson disease. Neurology. 2005 Feb 22; 64(4):664-9. PMID: 15728289.
    View in: PubMed
  139. Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging. 2005; 22(6):471-82. PMID: 15974638.
    View in: PubMed
  140. Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther. 2005 Mar; 105(3):267-310. PMID: 15737407.
    View in: PubMed
  141. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Logroscino G, Willett WC, Ascherio A. Folate intake and risk of Parkinson's disease. Am J Epidemiol. 2004 Aug 15; 160(4):368-75. PMID: 15286022.
    View in: PubMed
  142. Francis JW, Bastia E, Matthews CC, Parks DA, Schwarzschild MA, Brown RH, Fishman PS. Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS. Brain Res. 2004 Jun 11; 1011(1):7-13. PMID: 15140640.
    View in: PubMed
  143. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol. 2004 Mar 15; 159(6):547-55. PMID: 15003958.
    View in: PubMed
  144. Yu L, Frith MC, Suzuki Y, Peterfreund RA, Gearan T, Sugano S, Schwarzschild MA, Weng Z, Fink JS, Chen JF. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Res. 2004 Mar 12; 1000(1-2):156-73. PMID: 15053963.
    View in: PubMed
  145. Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, Chen JF, Ferrante RJ. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem. 2004 Feb; 88(3):538-44. PMID: 14720203.
    View in: PubMed
  146. Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol. 2004 Jan; 65(1):121-9. PMID: 14722243.
    View in: PubMed
  147. Schwarzschild MA, Chen J-F & Chase TN. Translating Adenosine A2A Receptor Biology into Novel Therapies for Parkinson's Disease. Neurology [journal supplemental issue]. 2003; S1-111.
  148. Urade Y, Eguchi N, Qu WM, Sakata M, Huang ZL, Chen JF, Schwarzschild MA, Fink JS, Hayaishi O. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology. 2003 Dec 09; 61(11 Suppl 6):S94-6. PMID: 14663019.
    View in: PubMed
  149. Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology. 2003 Dec 09; 61(11 Suppl 6):S74-81. PMID: 14663016.
    View in: PubMed
  150. Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, Chen JF. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 2003 Dec 09; 61(11 Suppl 6):S55-61. PMID: 14663012.
    View in: PubMed
  151. Castagnoli N, Petzer JP, Steyn S, Castagnoli K, Chen JF, Schwarzschild MA, Van der Schyf CJ. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology. 2003 Dec 09; 61(11 Suppl 6):S62-8. PMID: 14663013.
    View in: PubMed
  152. Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003 Nov; 184(1):285-94. PMID: 14637099.
    View in: PubMed
  153. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink JS, Linden J, Okusa MD. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003 Sep; 112(6):883-91. PMID: 12975473; PMCID: PMC193661.
    View in: PubMed, PubMed Central
  154. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003 Aug; 60(8):1059-64. PMID: 12925360.
    View in: PubMed
  155. Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol. 2003 Aug; 54(2):170-5. PMID: 12891669.
    View in: PubMed
  156. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2003 Jun; 18(6):646-51. PMID: 12784267.
    View in: PubMed
  157. Chen JF, Moratalla R, Yu L, Martín AB, Xu K, Bastia E, Hackett E, Alberti I, Schwarzschild MA. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology. 2003 Jun; 28(6):1086-95. PMID: 12700712.
    View in: PubMed
  158. Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg Med Chem. 2003 Apr 03; 11(7):1299-310. PMID: 12628657.
    View in: PubMed
  159. Sharma N & Schwarzschild MA. . Movement disorders during pregnancy. JH Noseworthy, editor. Neurologic Therapeutics: Principles and Practice. 2003; 1((Part 2)):1556 – 1558.
  160. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003 Mar 11; 60(5):790-5. PMID: 12629235.
    View in: PubMed
  161. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Uéda K, Young AB, Hyman BT, Ashe KH. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging. 2003 Mar-Apr; 24(2):245-58. PMID: 12498958.
    View in: PubMed
  162. Bastia E, Schwarzschild MA. DARPP chocolate: a caffeinated morsel of striatal signaling. Sci STKE. 2003 Jan 14; 2003(165):PE2. PMID: 12527819.
    View in: PubMed
  163. Chen J-F & Schwarzschild MA. Gene Knockout Approach to Adenosine A2A receptors in Parkinson’s disease. Drug Development Research. 2003; 58:354-367.
  164. Schwarzsdchild MA, Chen J-F, Chase TN. A2A antagonists for PD - A prime example of translational neuroscience. Neurology. 2003; 61(11 Suppl 6):S3-4.
  165. Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N, Schwarzschild MA. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem. 2002 Sep 27; 277(39):36040-4. PMID: 12130655.
    View in: PubMed
  166. Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol. 2002 Jun; 160(6):2231-44. PMID: 12057925; PMCID: PMC1850844.
    View in: PubMed, PubMed Central
  167. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002 Jun; 160(6):2009-18. PMID: 12057906; PMCID: PMC1850820.
    View in: PubMed, PubMed Central
  168. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 2002 Apr 23; 58(8):1154-60. PMID: 11971080.
    View in: PubMed
  169. Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett. 2002 Mar 29; 322(1):13-6. PMID: 11958832.
    View in: PubMed
  170. Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, Impagnatiello F, Schwarzschild MA, Chen JF. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci. 2002 Feb 01; 22(3):1054-62. PMID: 11826134.
    View in: PubMed
  171. Kanthasamy AG, Sharma N, Kirby ML & Schwarzschild MA. . Neuroprotective Strategies in Parkinson’s Disease. In: J Marwah, EH Lo, editors. Neuroprotection. 2002; 603-640.
  172. Gearan T, Castillo OA, Schwarzschild MA. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. Parkinsonism Relat Disord. 2001 Sep; 8(1):19-22. PMID: 11472876.
    View in: PubMed
  173. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Schwarzschild MA. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001 May 15; 21(10):RC143. PMID: 11319241.
    View in: PubMed
  174. Armstrong JM, Chen JF, Schwarzschild MA, Apasov S, Smith PT, Caldwell C, Chen P, Figler H, Sullivan G, Fink S, Linden J, Sitkovsky M. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J. 2001 Feb 15; 354(Pt 1):123-30. PMID: 11171087; PMCID: PMC1221636.
    View in: PubMed, PubMed Central
  175. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild MA. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1970-5. PMID: 11172060; PMCID: PMC29366.
    View in: PubMed, PubMed Central
  176. Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild MA & Chen J-F. . Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegerative processes. Drug Development Research. 2001; 52:379-386.
  177. Haskó G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabó C. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 2000 Oct; 14(13):2065-74. PMID: 11023991.
    View in: PubMed
  178. Apasov SG, Chen JF, Smith PT, Schwarzschild MA, Fink JS, Sitkovsky MV. Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity. Br J Pharmacol. 2000 Sep; 131(1):43-50. PMID: 10960067; PMCID: PMC1572291.
    View in: PubMed, PubMed Central
  179. Francis JW, Brown RH, Figueiredo D, Remington MP, Castillo O, Schwarzschild MA, Fishman PS, Murphy JR, vanderSpek JC. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J Neurochem. 2000 Jun; 74(6):2528-36. PMID: 10820215.
    View in: PubMed
  180. Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG, Aloyo VJ, Fink JS, Schwarzschild MA. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience. 2000; 97(1):195-204. PMID: 10771351.
    View in: PubMed
  181. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci. 1999 Nov 01; 19(21):9192-200. PMID: 10531422.
    View in: PubMed
  182. Schwarzschild MA, Cole RL, Meyers MA, Hyman SE. Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons. J Neurochem. 1999 Jun; 72(6):2248-55. PMID: 10349832.
    View in: PubMed
  183. Schwarzschild MA & Fink JS. Parkinsonism-Dementia Complex of Guam. In: Joseph AB, Young RR, editors. Movement Disorders in Neurology and Neuropsychiatry. 1999.
  184. Schwarzschild MA, Cole RL, Hyman SE. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons. J Neurosci. 1997 May 15; 17(10):3455-66. PMID: 9133371.
    View in: PubMed
  185. Schwarzschild M, Rordorf G, Bekken K, Buonanno F, Schmahmann JD. Normal-pressure hydrocephalus with misleading features of irreversible dementias: a case report. J Geriatr Psychiatry Neurol. 1997 Apr; 10(2):51-4. PMID: 9188018.
    View in: PubMed
  186. Schwarzschild MA. Movement Disorders. In: Cudkowicz M & Irizarry M, editors. Neurologic Disorders in Women. 1997; 133-138.
  187. Hyman SE, Cole RL, Schwarzschild MA, Konradi C, Cole D & Hope B. . Molecular mechanisms of striatal gene regulation: a critical role for glutamate in dopamine-mediated gene induction. In: Merchant K, editor. Pharmacological Regulation of Gene Expression in the CNS. 1996; 115-136.
  188. Schwarzschild MA, Dauer WT, Lewis SE, Hamill LK, Fink JS, Hyman SE. Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures. J Neurochem. 1994 Oct; 63(4):1246-54. PMID: 7523587.
    View in: PubMed
  189. Provenzale JM, Schwarzschild MA. Hemiballismus. AJNR Am J Neuroradiol. 1994 Aug; 15(7):1377-82. PMID: 7976952.
    View in: PubMed
  190. Schwarzschild MA. Nail in the Brain. [Images in Medicine series]. The New England Journal of Medicine. 1993; 328:620.
  191. Schwarzschild MA, Zigmond RE. Effects of peptides of the secretin-glucagon family and cyclic nucleotides on tyrosine hydroxylase activity in sympathetic nerve endings. J Neurochem. 1991 Feb; 56(2):400-6. PMID: 1703218.
    View in: PubMed
  192. Schwarzschild MA, Vale W, Corigliano-Murphy AC, Pisano JJ, Ip NY, Zigmond RE. Activation of ganglionic tyrosine hydroxylase by peptides of the secretin-glucagon family: structure-function studies. Neuroscience. 1989; 31(1):159-67. PMID: 2570376.
    View in: PubMed
  193. Zigmond RE, Schwarzschild MA, Rittenhouse AR. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu Rev Neurosci. 1989; 12:415-61. PMID: 2564757.
    View in: PubMed
  194. Schwarzschild MA, Zigmond RE. Secretin and vasoactive intestinal peptide activate tyrosine hydroxylase in sympathetic nerve endings. J Neurosci. 1989 Jan; 9(1):160-6. PMID: 2563276.
    View in: PubMed
  195. Rittenhouse AR, Schwarzschild MA, Zigmond RE. Both synaptic and antidromic stimulation of neurons in the rat superior cervical ganglion acutely increase tyrosine hydroxylase activity. Neuroscience. 1988 Apr; 25(1):207-15. PMID: 2899305.
    View in: PubMed
  196. Schwarzschild MA. The peptidergic and cholinergic regulation of tyrosine hydroxylase activity in a sympathetic ganglion and its end organs. 1988.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Schwarzschild's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (674)
Explore
_
Co-Authors (81)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
©2019 President and Fellows of Harvard College
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.